Find policies, billing codes, payers, states, and providers
Biomarker Testing for Autoimmune Rheumatic Disease
Customize your policy alerts
Sign up for Blue Cross Blue Shield - New Mexico Policy RPLAB011 alerts
Get alerted when Policy RPLAB011 changes without checking for updates manually.
Monitor payer policy activity
Reimbursement criteria for laboratory biomarker testing used to diagnose, evaluate, or monitor autoimmune rheumatic diseases for Blue Cross Blue Shield - New Mexico members and participating providers.
Document updated with literature review and Reimbursement Information edits; items #11, #12, #13 were edited for clarity and 'Tissue Specific Markers for Early Diagnosis of Sjögren's Disease' was added to #13.
Reimbursement Information edited for clarity on allowed frequency of biomarker testing and new non-reimbursable items added (e.g., Seronegative Rheumatoid Arthritis Profile; aisle® DX Disease Activity Index; Early Sjögren's Syndrome Profile).
Statement added: for individuals with painful and swollen joints and clinical suspicion of RA, testing for RF and/or anti-CCP may be reimbursable once per lifetime in individuals with stable symptoms; repeat testing only if significant change occurs.
Policy clarified that serum biomarker panel testing for RA disease management (e.g., Vectra DA, PrismRA) is not reimbursable; prior related policy CPCPLAB039 addressed Vectra DA.
Coverage Criteria for Biomarker Testing
COVERAGE CRITERIA
Coverage determinations for antibody and biomarker testing in autoimmune rheumatic disease.
ALL of the following
- Once during initial workup.
- Up to two additional tests per lifetime if new or more severe signs or symptoms of an autoimmune disease develop.
ALL of the following
- Once during initial workup.
- If initial testing did not result in a diagnosis of RA, up to two additional tests per lifetime if symptoms persist or additional symptoms of RA develop.
Condition-specific antibody testing (when indicated)
- Testing for anti-Jo-1 in a unique clinical subset of myositis.
- Testing for anti-SSA in the setting of lupus or Sjögren's syndrome.
Extracted coverage-related statements
Summarized reimbursement positions and changes from policy history.
Procedure Codes and Testing Frequency
| 81490 | AUTOIMMUNE RA ALYS 12 BMRK. |
| 81599 | UNLISTED MAAA. |
| 86038 | ANTINUCLEAR ANTIBODIES. |
| 86039 | ANTINUCLEAR ANTIBODIES (ANA). |
| 86200 | CCP ANTIBODY. |
| 86225 | DNA ANTIBODY NATIVE. |
| 86235 | NUCLEAR ANTIGEN ANTIBODY. |
| 86430 | RHEUMATOID FACTOR TEST QUAL. |
| 86431 | RHEUMATOID FACTOR QUANT. |
| 0039U | DNA ANTB 2STRAND HI AVIDITY. |
| 0522U | New code added per policy history |
| 0446U | Code added previously (policy history) |
| 0447U | Code added previously (policy history) |
| 0521U | Code added previously (policy history) |
| 86200 | CCP ANTIBODY (added to policy history) |
| 86340 | Immunoassay; analyte (added to policy history) |
| 86341 | Immunoassay; analyte (added to policy history) |
Documentation, Billing, and Reimbursement Notices
Submit accurate documentation and valid coding; respond to claim review requests
Providers must submit accurate documentation of services performed and submit claims using valid, industry-standard code sets and combinations. Claims are subject to code edit protocols and review; upon request, providers should supply any additional documentation the Plan requests.
- Use HIPAA-approved code sets and follow Uniform Billing, AMA CPT, HCPCS, ICD-10-CM/PCS, NDC, and CMS coding guidance.
- Claims may be reviewed against benefit terms, provider contract language, medical and reimbursement policies, and coding software logic.
- Be prepared to provide additional documentation upon request to support medical necessity and coding.
Account for reimbursement edits and added/updated codes from policy history
Review the Policy History for recent reimbursement edits and newly added procedure codes; reimbursements, allowed frequencies, and non-reimbursable tests have been updated in the policy history entries.
- Note newly added procedure codes in policy history (examples added: 86200, 86340, 86341, 0446U, 0447U, 0521U, 0522U).
- Recognize that reimbursement information was revised for allowed testing frequencies (e.g., RF/anti-CCP frequency clarifications, ANA frequency guidance) and that multiple proprietary biomarker panels were added to the non-reimbursable list.
- Policy history entries include dates and descriptions of these edits—providers should consult the policy history when submitting claims for affected tests.
Definitions and Non-Reimbursable Tests
Policy Revision History and Material Changes
Document updated with literature review; added statement that RF and/or anti-CCP testing may be reimbursable once per lifetime for individuals with stable symptoms with repeat testing only if significant change occurs, and codes 86200, 86340, 86341 were added.
Document updated with literature review; reimbursement information revised to clarify 'Once per lifetime in individuals with stable symptoms' and 'Repeat testing only if a significant change in symptoms occurs' were added to policy statements.
Policy RPLAB011 effective date published.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.